Repeat coronary angioplasty as the treatment of choice for restenosis

Kitazume, Hidemasa; Kubo, Ichiro; Iwama, Toru; Ageishi, Yoshio

doi:10.1016/s0002-8703(96)90301-4

Cited by 11 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a series of 1455 de novo lesions treated with PTCA, angiographic restenosis requiring repeat PTCA developed in 32% (842). Late patency was achieved in 93% of lesions with up to 3 PTCA procedures.…”

Section: Smith Et Al 2005 Acc/aha/scai Practice Guidelinesmentioning

confidence: 99%

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

Smith

Feldman²,

Hirshfeld³

et al. 2006

Journal of the American College of Cardiology

491

146

View full text Add to dashboard Cite

Section: Smith Et Al 2005 Acc/aha/scai Practice Guidelinesmentioning

confidence: 99%

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

Smith

Feldman²,

Hirshfeld³

et al. 2006

Journal of the American College of Cardiology

491

146

View full text Add to dashboard Cite

“…Late patency was achieved in 93% of lesions with up to 3 PTCA procedures. Only 23 lesions (1.6%) required 4 or more procedures (842).…”

Section: Pci In Cardiac Transplant Patientsmentioning

confidence: 99%

“…Long-term Long-term patency of the initial target lesion may be achieved with repeated balloon dilatations. In a series of 1455 de novo lesions treated with PTCA, angiographic restenosis requiring repeat PTCA developed in 32% (842). Late patency was achieved in 93% of lesions with up to 3 PTCA procedures.…”

Section: Pci In Cardiac Transplant Patientsmentioning

confidence: 99%

See 1 more Smart Citation

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Wilkins¹

2006

Circulation

350

View full text Add to dashboard Cite

“…These rates were even higher in certain subsets, such as longer lesions, smaller vessels, and patients with diabetes. Other complex lesion characteristics including ostial location,19 bifurcations,20 chronic occlusions,21 and prior restenosis22 have been associated with increased risk for restenosis. The mechanism of restenosis differs between PTCA alone and stenting.…”

mentioning

confidence: 99%

Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent

Bridges

Cutlip²

2008

MDER

View full text Add to dashboard Cite

Coronary artery disease remains one of the leading causes of death in the United States. Over the last 30 years, the development of coronary artery angioplasty and stenting has drastically reduced mortality during acute coronary syndromes while also reducing symptoms of chronic coronary artery disease. Unfortunately, the placement of stents in a coronary artery can be complicated by in-stent thrombosis or restenosis. In 2003–2004, a new generation of stents was introduced to the market with the goal of reducing the rate of restenosis. These stents, called drug eluting stents (DES), are coated with a pharmacological agent designed to reduce the neointimal hyperplasia associated with restenosis. Within a year, approximately 80% of all percutaneous coronary interventions performed within the US involved placement of a DES. In 2006, a controversy arose about the possibility of a statistically significant increased risk of acute stent thrombosis associated with DES especially when used for an “off label” indication. This risk was attributed to delayed endothelization. This controversy has led to a reduction in the use of DES along with longer use of dual platelet inhibition with aspirin and clopidogrel. Recently Medtronic introduced a new DES to the market called the Endeavor® stent – a zotarolimus eluting stent.

show abstract

Repeat coronary angioplasty as the treatment of choice for restenosis

Cited by 11 publications

References 4 publications

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent

Contact Info

Product

Resources

About

Repeat coronary angioplasty as the treatment of choice for restenosis

Cited by 11 publications

References 4 publications

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Advances in drug eluting stents &ndash; focus on the Endeavor&reg; zotarolimus stent

Contact Info

Product

Resources

About

Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent